Literature DB >> 33099476

Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma.

Yoon Ah Cho1,2, Sangjoon Choi1, Sujin Park1, Cheol-Keun Park1,3, Sang Yun Ha4.   

Abstract

BACKGROUND/AIM: Pregnancy up-regulated non-ubiquitous calmodulin kinase (PNCK) is a member of calmodulin kinase, and overexpression of PNCK with involvement in carcinogenesis have been reported in HER-2 amplified breast cancer, clear cell renal cell carcinoma and nasopharygeal carcinoma. However, the expression of PNCK and its clinical implication have not been elucidated in hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: We investigated PNCK expression at both the protein and mRNA level using immunohistochemistry (IHC) and microarray gene expression profiling in HCC tissue samples, and evaluated its association with clinicopathological parameters and their potential prognostic significance.
RESULTS: High PNCK protein expression and high PNCK mRNA level was observed in 61.7% and 34.7% of total HCC cases, respectively. PNCK mRNA level was higher in tumor tissues than in background non-tumor tissues, and significantly correlated with protein expression by IHC. High PNCK expression was associated with higher Edmondson grade, intrahepatic metastasis, microvascular invasion and higher AFP levels. Patients with high PNCK expression showed shorter recurrence-free survival and disease-specific survival, and high mRNA expression of PNCK was an independent prognostic factor in disease-specific survival.
CONCLUSION: Up-regulation of PNCK expression as well as its association with poor prognosis was demonstrated in HCC. PNCK might be a prognostic biomarker of HCC, and could be a potential candidate therapeutic target. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  EGFR; Hepatocellular carcinoma; PNCK; calmodulin; prognosis

Mesh:

Substances:

Year:  2020        PMID: 33099476      PMCID: PMC7675661          DOI: 10.21873/cgp.20229

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  22 in total

1.  Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.

Authors:  Taebum Lee; Cheol-Keun Park; Sang Yun Ha
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

2.  Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling.

Authors:  Ho-Yeong Lim; Insuk Sohn; Shibing Deng; Jeeyun Lee; Sin Ho Jung; Mao Mao; Jiangchun Xu; Kai Wang; Stephanie Shi; Jae Won Joh; Yoon La Choi; Cheol-Keun Park
Journal:  Ann Surg Oncol       Date:  2013-06-26       Impact factor: 5.344

3.  Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma.

Authors:  S Kira; T Nakanishi; S Suemori; M Kitamoto; Y Watanabe; G Kajiyama
Journal:  Liver       Date:  1997-08

4.  KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma.

Authors:  Akihiro Kitagawa; Takaaki Masuda; Junichi Takahashi; Taro Tobo; Miwa Noda; Yosuke Kuroda; Qingjiang Hu; Yuta Kouyama; Yuta Kobayashi; Shotaro Kuramitsu; Kuniaki Sato; Atsushi Fujii; Yukihiro Yoshikawa; Hiroaki Wakiyama; Dai Shimizu; Yusuke Tsuruda; Hidetoshi Eguchi; Yuichiro Doki; Masaki Mori; Koshi Mimori
Journal:  Cancer Genomics Proteomics       Date:  2020 Mar-Apr       Impact factor: 4.069

5.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

6.  Cloning, characterization, and chromosomal localization of Pnck, a Ca(2+)/calmodulin-dependent protein kinase.

Authors:  H P Gardner; J V Rajan; S I Ha; N G Copeland; D J Gilbert; N A Jenkins; S T Marquis; L A Chodosh
Journal:  Genomics       Date:  2000-01-15       Impact factor: 5.736

7.  Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.

Authors:  T Kumada; S Nakano; I Takeda; K Sugiyama; T Osada; S Kiriyama; Y Sone; H Toyoda; S Shimada; M Takahashi; T Sassa
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

8.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

9.  Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation.

Authors:  Tushar B Deb; Christine M Coticchia; Robert Barndt; Hong Zuo; Robert B Dickson; Michael D Johnson
Journal:  Am J Physiol Cell Physiol       Date:  2008-06-18       Impact factor: 4.249

10.  Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma.

Authors:  Song Wu; Zhaojie Lv; Yong Wang; Liang Sun; Zhimao Jiang; Congjie Xu; Jun Zhao; Xiaojuan Sun; Xianxin Li; Lijun Hu; Aifa Tang; Yaoting Gui; Fangjian Zhou; Zhiming Cai; Rongfu Wang
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more
  5 in total

1.  Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma.

Authors:  Liu Yang; Long-Fei Zeng; Guo-Qing Hong; Qing Luo; Xing Lai
Journal:  J Immunol Res       Date:  2022-07-12       Impact factor: 4.493

2.  Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy.

Authors:  Huasheng Huang; Xiwen Liao; Guangzhi Zhu; Chuangye Han; Xiangkun Wang; Chengkun Yang; Xin Zhou; Tianyi Liang; Ketuan Huang; Tao Peng
Journal:  Pharmgenomics Pers Med       Date:  2022-03-29

3.  Upregulation of PNCK Promotes Metastasis and Angiogenesis via Activating NF-κB/VEGF Pathway in Nasopharyngeal Carcinoma.

Authors:  Xiaochuan Chen; Youliang Weng; Ying Li; Wankai Fu; Zongwei Huang; Yuhui Pan; Wenquan Hong; Wanzun Lin; Xiandong Lin; Sufang Qiu
Journal:  J Oncol       Date:  2022-04-30       Impact factor: 4.501

4.  Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study.

Authors:  Yu Zhu; Ling-Ling Gu; Fa-Biao Zhang; Guo-Qun Zheng; Ting Chen; Wei-Dong Jia
Journal:  Can J Gastroenterol Hepatol       Date:  2022-08-23

5.  m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.

Authors:  Jianhao Li; Weiwei Wang; Yubing Zhou; Liwen Liu; Guizhen Zhang; Kelei Guan; Xichun Cui; Xin Liu; Maoxin Huang; Guangying Cui; Ranran Sun
Journal:  Front Cell Dev Biol       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.